Identification of the timing of neuronal hypoexcitability within ALS patient disease progression, the exact mechanisms by which mutant TDP-43 lowers synaptic GluR1, and modulation of synaptic GluR1 levels, may provide novel therapeutic targets for the treatment of this devastating neurodegenerative disease. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.